Skin wrinkles and dry skin Skin and Connective Tissue Diseases
Conditions
Interventions
Participants are randomly allocated to one of two treatment groups in equal proportions applying block randomization. Participants take one daily capsule of the test product (Bifidobacterium in microc
Sponsors
Danisco Sweeteners Oy
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Korean female subjects aged between 30 and 60 2. Dry skin on their cheek (hydration value is below 48 A.U. by Corneometer®) 3. Skin wrinkles over grade 3 by DERMAPRO standard photograph 4. No chronic or acute disease including skin disease 5. Signed informed consent 6. Cooperative and available for follow-up during the study period
Exclusion criteria
Exclusion criteria: 1. Consumed probiotics as dietary supplements, food or beverage products during the last 2 weeks 2. Pregnant, nursing or planning to become pregnant 3. Irritation or symptomatic allergy for food including ingredients of cosmetic, medical and test product. 4. Took oral or topical antibiotics during the previous 3 months 5. Took oral retinoid/steroid drug or topical application included steroid during previous 6 months 6. Use functional cosmetics for improvement of skin wrinkle, hydration and elasticity within 3 months 7. Have an experience on the test site (skin decortications, botox and other skin treatment) 8. Participated in a previous study without an appropriate intervening period (3 months) between studies 9. Have a disease which affects the study (e.g. cardiovascular, kidney, liver, thyroid, gastrointestinal disease, gout) 10. Any skin disease (e.g. atopic dermatitis) at the test site 11. Any chronic disease (e.g. diabetes, asthma, high blood pressure) or psychiatric disorder (e.g. depression, schizophrenia, alcoholism, drug addiction) 12. Take a medicine for the treatment of obesity (e.g. antidepressants, anorectics), contraceptives, hormones or diuretics 13. Drink excessive alcohol (over 30 g alcohol per day) 14. Sensitive or hypersensitive skin 15. Damaged skin in or around the test area which includes sunburn, tattoos, scars or other disfiguration on the test area 16. Abnormal result in screening clinical chemical analysis by medical specialist 17. Problem which may interfere with the aim of the study as judged by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Skin wrinkles measured with PRIMOS® premium from Crow’s feet at 4, 8 and 12 weeks 2. Skin hydration measured from cheek, forearm and back of hand with corneometer and moisturemeter at baseline, 4, 8 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Transepidermal water loss measured with evaporimeter from cheek, forearm and back of hand at baseline, 4, 8 and 12 weeks 2. Skin elasticity measured with cutometer from cheek at baseline, 4, 8 and 12 weeks 3. Skin gloss measured with SkinGlossMeter from cheek at baseline, 4, 8 and 12 weeks 4. Body composition measured with Inbody 330 analyzer at baseline and 2 weeks 5. Facial image measured using VISIA-CR® skin analysis system at baseline and 4, 8 and 12 weeks 6. Product efficacy assessed using an efficacy questionnaire at 4, 8 and 12 weeks 7. Product usability assessed using a usability questionnaire at 12 weeks | — |
Countries
Korea, South
Contacts
Public ContactRyu Ja Hyun
Outcome results
None listed